Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KEYNOTE-177

UK flag

NHS medicine spend to remain flat for two years

But UK drug pricing deal stops short of PPRS overhaul to value-based system

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

NICE unmoved by Pixuvri access scheme

England’s HTA body once again denies Cell Therapeutics' blood cancer treatment

- PMLiVE

NICE backs Roche’s MabThera in rare autoimmune disease

Overturns previous negative draft guidance from England's cost-effectiveness body

healthcare data technology

Data technology and value-based pricing

The value of adding post-approval data collating, monitoring and analysis to any discussion on drug pricing systems

- PMLiVE

UK’s Cancer Drugs Fund given new lease of life

Government invests £400m and pledges Fund will remain until 2016

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links